UK's Oxford Biomedica falls after keeping 2026 expectations unchanged

Oxford BioMedica

24/02/2026 08:31

** Shares of British cell and gene therapy manufacturer Oxford Biomedica OXB.L down 5.5% at 730p

** OXB keeps expectations for 2026 unchanged, reiterates guidance

** Co expects rev to increase about 30%, between 166 million pounds ($223.64 million) to 169 million pounds for FY 2025

** YTD, stock up ~19.51%

($1 = 0.7423 pounds)

(Reporting by Ankita Bora in Bengaluru)

((Ankita.Bora@thomsonreuters.com))